Sei Investments Co. Acquires 34,540 Shares of Integra LifeSciences Holdings Corporation $IART

Sei Investments Co. boosted its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 58.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 93,726 shares of the life sciences company’s stock after acquiring an additional 34,540 shares during the quarter. Sei Investments Co. owned approximately 0.12% of Integra LifeSciences worth $883,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Hsbc Holdings PLC bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $879,000. Tejara Capital Ltd raised its position in Integra LifeSciences by 42.6% in the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares during the last quarter. UBS Group AG lifted its holdings in Integra LifeSciences by 211.7% during the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock worth $5,079,000 after buying an additional 277,745 shares in the last quarter. Systematic Financial Management LP lifted its holdings in Integra LifeSciences by 4.5% during the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after buying an additional 48,094 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in Integra LifeSciences in the 1st quarter valued at $280,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Trading Up 4.9%

IART opened at $18.24 on Friday. The firm’s fifty day moving average is $18.00 and its two-hundred day moving average is $13.81. The firm has a market cap of $1.42 billion, a PE ratio of -202.64, a price-to-earnings-growth ratio of 1.47 and a beta of 1.21. Integra LifeSciences Holdings Corporation has a twelve month low of $8.70 and a twelve month high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on IART shares. Truist Financial boosted their target price on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Weiss Ratings cut Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Wells Fargo & Company boosted their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Thursday, June 18th. Finally, Citigroup reiterated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences currently has a consensus rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.